Who founded Pairidex, Inc.?

Pairidex, Inc. was founded by Grant Challen in 2023.

Who are Pairidex, Inc.'s investors?

Pairidex, Inc.'s investors include BioGenerator Ventures, iSelect Fund.

How much funding has Pairidex, Inc. raised?

Pairidex, Inc. has disclosed $1.1M raised across 1 round.

Where is Pairidex, Inc. headquartered?

Pairidex, Inc. is headquartered in St. Louis, US.

Pairidex, Inc.

St. Louis, US · Founded 2023 · Delaware corporation · 2 known investors

Pairidex offers FusionMRD, a personalized digital droplet PCR (ddPCR) assay that detects and quantifies oncogenic gene fusions from a standard peripheral blood sample to monitor treatment response and minimal residual disease in gene fusion-driven blood cancers such as leukemia. It is sold as a commercial service for oncologists and clinical researchers to support treatment decisions and shorten clinical trial timelines.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Pairidex, Inc. was founded in 2023 by Grant Challen.

Grant ChalleninCo-Founder & Scientific Advisor

Allyson MayerinInterim COOPrincipal at BioGenerator Ventures

Andrew YoungFounder & CSO

Paul KortschakinCEO

Board

Todd DruleyBoard director

Crystal WinkelerBoard directorManaging Director at BioGenerator Ventures

Investors · 2

BioGenerator Ventures✓ verifiedSt. Louis · $50K – $250Kvia Crystal Winkeler · board

iSelect FundSt. Louis · $250K – $2M

Reported raises · per SEC filings

Form D private placements

$1.1M disclosed across 1 round · 2024

▶$1.1MraisedFeb 2025 · 16 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Todd DruleyDirector
Crystal WinkelerDirector
Allyson MayerExecutive Officer
Andrew YoungExecutive Officer, Director

Offering amount: $1.1M
Amount sold: $1.1M
Minimum investment: $25K
First sale: May 2024
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Predxbio4 shared keywordsPredxBio analyzes spatial multi-omic tissue data to identify response-defining biology, offering a decision-intelligence platform called SpaceIQ that supports drug development from discovery through clinical trials. It serves biopharma teams with biomarker strategy, patient stratification, and trial optimization insights.

Companies competing with Pairidex, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Pairidex, Inc. do?: Pairidex offers FusionMRD, a personalized digital droplet PCR (ddPCR) assay that detects and quantifies oncogenic gene fusions from a standard peripheral blood sample to monitor treatment response and minimal residual disease in gene fusion-driven blood cancers such as leukemia. It is sold as a commercial service for oncologists and clinical researchers to support treatment decisions and shorten clinical trial timelines.
Who founded Pairidex, Inc.?: Pairidex, Inc. was founded by Grant Challen in 2023.
Who are Pairidex, Inc.'s investors?: Pairidex, Inc.'s investors include BioGenerator Ventures, iSelect Fund.
How much funding has Pairidex, Inc. raised?: Pairidex, Inc. has disclosed $1.1M raised across 1 round.
Where is Pairidex, Inc. headquartered?: Pairidex, Inc. is headquartered in St. Louis, US.